<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87192">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01704651</url>
  </required_header>
  <id_info>
    <org_study_id>12-004082</org_study_id>
    <nct_id>NCT01704651</nct_id>
  </id_info>
  <brief_title>Accelerating Gastrointestinal Recovery</brief_title>
  <official_title>Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jamie N. Bakkum-Gamez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cubist Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine whether an oral perioperative medication (alvimopan--a
      selective mu antagonist) improves bowel recovery over placebo after surgery for ovarian
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Postoperative length of hospital stay</measure>
    <time_frame>Patients will be followed for the duration of their hospital stay, an expected average of 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative ileus incidence</measure>
    <time_frame>Patients will be followed for 30 days postop</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Alvimopan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvimopan</intervention_name>
    <description>Perioperative administration of oral alvimopan</description>
    <arm_group_label>Alvimopan</arm_group_label>
    <other_name>Entereg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Perioperative administration of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Females at least 18 years of age

          -  Have an American Society of Anesthesiologists (ASA) Score of I to III

          -  Are consented for primary, interval, or secondary cytoreduction for ovarian, tubal,
             or peritoneal cancer

          -  Are scheduled to have their nasogastric tube removed before the first postoperative
             dose of study medication

          -  Are able to understand the study procedures, have agreed to participate in the study
             program, and have voluntarily provided informed consent

        Exclusion criteria:

          -  Females younger than 18 years of age

          -  Known non-gynecologic malignancy presenting with similar signs/symptoms as ovarian,
             tubal, or peritoneal cancer.

          -  Have taken more than 7 consecutive days of therapeutic doses of opioids immediately
             prior to surgery

          -  Use illicit drugs or abuse alcohol

          -  Have had a prior total colectomy, gastrectomy, gastric bypass, or have a functional
             colostomy or ileostomy

          -  Have an ongoing history of short bowel syndrome, chronic constipation (â‰¤3 spontaneous
             bowel movements per week) or chronic diarrhea

          -  Have received radiation therapy to the abdomen or pelvis within 3 months of scheduled
             surgery

          -  Have chemotherapy or radiation induced bowel dysfunction

          -  Are pregnant (identified by a positive urine or serum pregnancy test) or lactating,
             or are not postmenopausal (no menses for at least 1 year) and are of childbearing
             potential and not using an accepted method of birth control (ie, surgical
             sterilization, intrauterine contraceptive device, oral contraceptive, diaphragm, or
             condom in combination with contraceptive cream, jelly, or foam, or abstinence)

          -  Have participated in another investigational drug or medical device study within 30
             days of surgery or will be enrolled in another investigational drug or medical device
             study or any study in which active patient participation is required outside normal
             hospital data collection during the course of this study

          -  Have clinically significant laboratory abnormalities at screening that would result
             in the cancellation of surgery

          -  Have a diagnosis of severe hepatic insufficiency or end stage renal disease.

          -  Have a history of previous surgeries, illness, or behavior that in the opinion of the
             investigator might confound the study results or pose additional risk in
             administering the study procedures

          -  Are unable to understand the study procedures and are not able to voluntarily
             provided informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie Bakkum-Gamez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maureen A Lemens, BSN, RN</last_name>
    <phone>507-293-1487</phone>
    <email>lemens.maureen@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marla Kay S Sommerfield</last_name>
    <phone>507-266-3053</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen A Lemens, BSN, RN</last_name>
      <phone>507-293-1487</phone>
      <email>lemens.maureen@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>October 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jamie N. Bakkum-Gamez</investigator_full_name>
    <investigator_title>Consultant and Assistant Professor of Obstetrics-Gynecology,</investigator_title>
  </responsible_party>
  <keyword>Ovary</keyword>
  <keyword>Ovarian</keyword>
  <keyword>Fallopian</keyword>
  <keyword>Peritoneal</keyword>
  <keyword>Cancer</keyword>
  <keyword>Gynecological</keyword>
  <keyword>Female</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
